Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases.Lancet. 1896; ii: 104-107
- La radiothérapie indirecte, ou dirigée par les corrélations organiques.Arch Elect Med. 1922; 32: 264
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women.Lancet. 1992; 339: 1-15
- Combination chemotherapy as an adjuvant treatment in operable breast cancer.N Engl J Med. 1976; 294: 405-410
- Ovarian ablation in early breast cancer: overview of the randomized trials.Lancet. 1996; 348: 1189-1196
- American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women With Early-Stage Invasive Breast Cancer.J Clin Oncol. 2011; 29: 3939-3942
- Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: Results of the International Breast Cancer Study Group Trial VI.Eur J Cancer. 1998; 34: 632-640
- Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer.J Clin Oncol. 2006; 24: 5769-5779
- Amenorrhea from breast cancer therapy e not a matter of dose.N Engl J Med. 2010; 363: 2268-2270
- Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.J Clin Oncol. 2006; 24: 1332-1341
- Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?.Lancet. 2000; 355: 1869-1874
- Adjuvant therapy for very young women with breast cancer: need for tailored treatments.J Natl Cancer Inst Monogr. 2001; 30: 44-51
- Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea e a report from the Korean Breast Cancer Society.J Clin Oncol. 2007; 26: 2360-2368
- Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: A prospective study.J Clin Oncol. 2006; 24: 1045-1051
- Risk of menopause during the first year after breast cancer diagnosis.J Clin Oncol. 1999; 17: 2365-2370
- Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: Caution and suggested guidelines.J Clin Oncol. 2006; 24: 2444-2447
- Incidence and predictors of ovarian function recovery in breast cancer patients with chemotherapy-induced amenorrhea who switched from tamoxifen to exemestane.Ann Oncol. 2013; 24: 674-679
- Incidence and predictive factors for recovery of ovarian function in amenorrheic women in their 40s treated with letrozole.J Clin Oncol. 2016; 34: 1594-1600
- Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials.Breast. 2013; 22: 1094-1100
- Adjuvant ovarian suppression in premenopausal breast cancer.N Engl J Med. 2015; 372: 436-446
- Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression.J Clin Oncol. 2016; 34: 1689-1701
- Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor–positive breast cancer (E-3193, INT-0142): A trial of the Eastern Cooperative Oncology Group.J Clin Oncol. 2014; 32: 3948-3958
- Tailoring adjuvant endocrine therapy for premenopausal breast cancer.N Engl J Med. 2018; 379: 122-137
- Adding ovarian suppression to tamoxifen for premenopausal breast cancer: A randomized phase III trial.J Clin Oncol. 2019; 37: 862-866
- Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the Suppression of Ovarian Function Trial.J Clin Oncol. 2016; 34: 1601-1610
- Absolute benefits of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials.J Clin Oncol. 2016; 34: 2221-2231
- Absolute improvements in freedom from distant recurrence by tailoring adjuvant endocrine therapies for premenopausal women with hormone receptor-positive HER2-negative breast cancer: results from TEXT and SOFT.J Clin Oncol. 2020; 38: 1293-1303
- Tailoring adjuvant endocrine therapy for premenopausal women: absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with HR+/HER2- breast cancer, as investigated in the TEXT and SOFT clinical trials, according to composite risk.(Available at:) (Accessed 19 June 2022)
- Randomized comparison of adjuvant aromatase inhibitor exemestane plus ovarian function suppression (OFS) vs tamoxifen plus OFS in premenopausal women with hormone receptor-positive early breast cancer: update of the combined TEXT and SOFT trials.Cancer Res. 2022; 82 (GS2-05)
- Aromatase inhibitors versus tamoxifen in premenopausal women with estrogen receptor-positive early breast cancer treated with ovarian suppression: patient level meta-analysis of 7,030 women in four randomized trials.Lancet Oncol. 2022; 23: 382-392
- Zolendronic acid prevents cancer treatment induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Study Group.J Clin Oncol. 2007; 25: 820-828
- Premenopausal women with early breast cancer treated by oestradiol suppression have severely deteriorated bone microstructure: A cross sectional study.Bone. 2017; 103: 131-135
- Endocrine therapy plus zolendronic acid in premenopausal breast cancer.N Engl J Med. 2009; 360: 679-691
- Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.Ann Oncol. 2015; 26: 313-320
- Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.N Engl J Med. 2015; 372: 923-932
- Gonadotropin-Releasing Hormone Agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta-analysis of individual patient–level data.J Clin Oncol. 2018; 36: 198-1990
- Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?.Ann Oncol. 2008; 19: 1231-1241
- Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.N Engl J Med. 2019; 380: 2395-2405
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.N Engl J Med. 2021; 385: 2336-2347
- 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.Lancet Oncol. 2021; 22: 476-488
- Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93.Breast Cancer Res Treat. 2009; 113: 137-144
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
